Yungjin Pharm Co Ltd Net Assets
Yungjin Pharm Co Ltd net assets. Based on the latest financial reports, Yungjin Pharm Co Ltd (003520) has net assets worth ₩90.02 Billion KRW (≈ $61.00 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩246.25 Billion ≈ $166.88 Million USD) and total liabilities (₩156.23 Billion ≈ $105.88 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 003520 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩90.02 Billion |
| % of Total Assets | 36.56% |
| Annual Growth Rate | -1.19% |
| 5-Year Change | -21.52% |
| 10-Year Change | -10.58% |
| Growth Volatility | 6.89 |
Net Assets of Yungjin Pharm Co Ltd (2013–2024)
Net assets of Yungjin Pharm Co Ltd from 2013 to 2024. This chart illustrates how Yungjin Pharm Co Ltd's net assets have evolved over time, based on quarterly financial data. See net asset quality index of Yungjin Pharm Co Ltd to measure how much of total assets are equity-financed.
Annual Net Assets for Yungjin Pharm Co Ltd (2013–2024)
The table below shows the annual net assets of Yungjin Pharm Co Ltd from 2013 to 2024. For live market cap and overall valuation, see 003520 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩89.80 Billion ≈ $60.86 Million |
+0.19% |
| 2023-12-31 | ₩89.63 Billion ≈ $60.74 Million |
-0.26% |
| 2022-12-31 | ₩89.87 Billion ≈ $60.90 Million |
-14.32% |
| 2021-12-31 | ₩104.89 Billion ≈ $71.08 Million |
-8.34% |
| 2020-12-31 | ₩114.43 Billion ≈ $77.55 Million |
-1.14% |
| 2019-12-31 | ₩115.75 Billion ≈ $78.44 Million |
+3.71% |
| 2018-12-31 | ₩111.61 Billion ≈ $75.63 Million |
-6.72% |
| 2017-12-31 | ₩119.65 Billion ≈ $81.08 Million |
+12.70% |
| 2016-12-31 | ₩106.17 Billion ≈ $71.95 Million |
+5.72% |
| 2015-12-31 | ₩100.42 Billion ≈ $68.06 Million |
-0.36% |
| 2014-12-31 | ₩100.79 Billion ≈ $68.30 Million |
-1.62% |
| 2013-12-31 | ₩102.45 Billion ≈ $69.43 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Yungjin Pharm Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 265.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Yungjin Pharm Co Ltd Net Assets Breakdown (December 2024)
Yungjin Pharm Co Ltd net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩107.45 Billion | 119.65% |
| Total Equity | ₩89.80 Billion | 100.00% |
Yungjin Pharm Co Ltd Competitors by Market Cap
The table below lists competitors of Yungjin Pharm Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wheels Up Experience Inc
NYSE:UP
|
$116.03 Million |
|
CAPRAL LTD.
F:CBZ
|
$116.04 Million |
|
Lotte Chemical Titan Tbk PT
JK:FPNI
|
$116.12 Million |
|
Winchester Bancorp, Inc. Common Stock
NASDAQ:WSBK
|
$116.13 Million |
|
TK Chemical Corporation
KQ:104480
|
$115.81 Million |
|
Northcliff Resources Ltd
TO:NCF
|
$115.80 Million |
|
K N Kenanga Holdings Bhd
KLSE:6483
|
$115.79 Million |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
$115.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Yungjin Pharm Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 89,632,344,150 to 89,803,131,310, a change of 170,787,160 (0.2%).
- Net income of 1,232,792,240 contributed positively to equity growth.
- Other factors decreased equity by 1,062,005,080.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩1.23 Billion | +1.37% |
| Other Changes | ₩-1.06 Billion | -1.18% |
| Total Change | ₩- | 0.19% |
Book Value vs Market Value Analysis
This analysis compares Yungjin Pharm Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.90x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.43x to 1.90x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩654.21 | ₩935.00 | x |
| 2018-12-31 | ₩610.23 | ₩935.00 | x |
| 2019-12-31 | ₩632.89 | ₩935.00 | x |
| 2020-12-31 | ₩625.68 | ₩935.00 | x |
| 2021-12-31 | ₩573.48 | ₩935.00 | x |
| 2022-12-31 | ₩491.38 | ₩935.00 | x |
| 2023-12-31 | ₩490.08 | ₩935.00 | x |
| 2024-12-31 | ₩491.02 | ₩935.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Yungjin Pharm Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.49%
- • Asset Turnover: 1.08x
- • Equity Multiplier: 2.61x
- Recent ROE (1.37%) is above the historical average (-1.53%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 11.46% | 7.50% | 0.92x | 1.65x | ₩1.50 Billion |
| 2014 | 0.90% | 0.54% | 0.94x | 1.78x | ₩-9.17 Billion |
| 2015 | 3.37% | 1.99% | 0.88x | 1.93x | ₩-6.66 Billion |
| 2016 | 3.96% | 2.18% | 0.97x | 1.88x | ₩-6.41 Billion |
| 2017 | 1.56% | 0.96% | 0.96x | 1.70x | ₩-10.10 Billion |
| 2018 | -5.47% | -3.27% | 0.95x | 1.76x | ₩-17.26 Billion |
| 2019 | 4.35% | 2.28% | 1.10x | 1.73x | ₩-6.55 Billion |
| 2020 | -0.12% | -0.06% | 1.11x | 1.64x | ₩-11.58 Billion |
| 2021 | -11.04% | -5.91% | 1.01x | 1.85x | ₩-22.07 Billion |
| 2022 | -24.44% | -10.06% | 1.08x | 2.26x | ₩-30.95 Billion |
| 2023 | -4.32% | -1.65% | 1.04x | 2.53x | ₩-12.84 Billion |
| 2024 | 1.37% | 0.49% | 1.08x | 2.61x | ₩-7.75 Billion |
Industry Comparison
This section compares Yungjin Pharm Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $490,498,627,337
- Average return on equity (ROE) among peers: 5.97%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Yungjin Pharm Co Ltd (003520) | ₩90.02 Billion | 11.46% | 1.74x | $115.89 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.62 Billion | 7.70% | 0.48x | $98.05 Million |
| Yuhan Corp. (000100) | $1.12 Trillion | 8.27% | 0.18x | $3.84 Billion |
| Yuhan Corp Preferred (000105) | $2.36 Trillion | 8.22% | 0.36x | $45.29 Million |
| Yuyu Pharma (000220) | $82.83 Billion | 5.48% | 0.47x | $40.03 Million |
| Yuyu Pharma Inc (000225) | $78.29 Billion | 7.52% | 0.42x | $13.08 Million |
| Yuyu Pharma Inc (000227) | $78.29 Billion | 7.52% | 0.42x | $32.56 Million |
| Ildong Holdings Co Ltd (000230) | $349.98 Billion | 5.99% | 1.02x | $43.17 Million |
| Samil Pharm (000520) | $70.03 Billion | 11.32% | 0.65x | $108.19 Million |
| Donga Socio Holdings (000640) | $306.84 Billion | 8.70% | 1.30x | $379.59 Million |
| Jw Pharmac (001060) | $230.09 Billion | -10.98% | 1.49x | $349.95 Million |
About Yungjin Pharm Co Ltd
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. The company offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. It also provides vitamins, minerals, and other products; and APIs. The com… Read more